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Background/aim: In immunosuppressed patients, strongyloidiasis can be lifethreatening because of hyperinfection or dissemination.
Therefore, diagnosis of S. stercoralis is important in immunosuppressed patients with chronic strongyloidiasis. In this study, our objective
was to investigate the presence of S. stercoralis antibodies by an ELISA method in immunosuppressed patients.
Materials and methods: A total of 100 immunosuppressed patients’ sera were included in the study. Forty-two of the patients were
receiving immunosuppressive therapies for cancer or being treated for hematopoietic malignancies, 38 of the patients were receiving
immunosuppressive drugs for rheumatic diseases, 14 were receiving immunosuppressive therapies for liver transplantation. Two of the
patients were being treated for HIV infection and 4 were being treated for hypogammaglobulinemia. As control group, 50 individuals
without a known disease were included in the study. The presence of IgG antibodies against S. stercoralis was investigated with a
commercial ELISA kit.
Results: S. stercoralis antibody test was positive in 4 of 100 (4%) sera from immunosuppressed patients. All control patients were
negative for S. stercoralis.
Conclusion: Strongyloidiasis can be a lifelong chronic infection if not treated. In patients who are going to receive immunosuppressive
therapy, it should be tested before treatment, as it can become a disseminated and life-threatening infectious disease.
Key words: Strongyloides stercoralis, strongyloidiasis, immunosuppression, serology, parasitic infection

1. Introduction
S. stercoralis is a soil-transmitted intestinal nematode
that causes strongyloidiasis in humans. It is estimated
that 30–100 million people are infected with S. stercoralis
worldwide. Strongyloidiasis is endemic in tropical and
subtropical areas especially where the sanitation conditions
are poor (1).
The infection is acquired through contact with soil that
is contaminated with free-living larvae. The larvae proceed
via venous circulation, migrate to the lungs, are swallowed
and reach the small intestine where they develop into adult
parasites. Rhabditiform larvae are excreted in stool and
transform into infective filariform larvae. The parasite can
cause autoinfection which may lead persistent infections
(1,2) .

Most of the S. stercoralis infections are asymptomatic.
Symptomatic infection is usually characterized by
gastrointestinal symptoms such as diarrhea and abdominal
pain or skin manifestations like itching and urticaria (3).
S. stercoralis infection can be severe and lifethreatening in patients with immunosuppression. In this
case, hyperinfection or dissemination of strongyloidiasis
that leads to systemic sepsis, and multiorgan failure may
develop. Hyperinfection syndrome is defined as accelerated
autoinfection. Disseminated infection occurs when larvae
migrate into organs other than the skin, gastrointestinal
tract, or lungs. Predisposing risk factors for developing
disseminated infection and hyperinfection syndrome
are immunosuppressive therapies for immune-mediated
disorders, infections with the human immunodeficiency
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virus (HIV), hematopoietic malignancies, and solid organ
transplants (4).
Diagnosis of asymptomatic S. stercoralis infection
in immunosuppressed patients is important to prevent
life-threatening complications. If strongyloidiasis
is diagnosed early, it is easily treatable with oral
antihelmintic drugs (4). Because of the low parasite load
and irregular larval output, diagnosis may be difficult
by stool examination (5). Serological methods such as
enzyme-linked immunosorbent assay (ELISA) or indirect
immunofluorescent test (IFAT) and molecular tests may
be alternative diagnostic methods for rapid detection of S.
stercoralis infection (6).
In this study, our objective was to investigate the
presence of S. stercoralis antibodies in the serum samples
by using an ELISA method in immunosuppressed patients.
2. Materials and methods
2.1. Patients
A total of 100 immunosuppressed patients’ sera were
included in the study. In this patient group ranging
from 18 to 66 years of age, 52 patients were male and
48 were female. Forty-two of the patients were receiving
immunosuppressive therapies for cancers such as lung
cancer and breast cancer or being treated for hematopoietic
malignancies such as lymphoma. Thirty-eight of the
patients were receiving immunosuppressive drugs
for rheumatic diseases such as ankylosing spondylitis
and rheumatoid arthritis. Fourteen of the patients
were receiving immunosuppressive therapies for liver
transplantation. Two of the patients were being treated for
HIV infection and four of the patients were being treated
for hypogammaglobulinemia. As the control group, 50
individuals without a known disease, i.e. apparently
healthy, and not receiving immunosuppressed treatment
were included in the study. In the control group, there were
29 males and 21 females whose ages ranged from 19 to 63.
2.2. Blood samples
A total of 150 blood samples were collected. A hundred
of them were from the patients that are shown in Table
and 50 were from the healthy subjects. Sera were separated
from blood and stored at −20 °C until analysis.
2.3. ELISA testing
The presence of IgG antibodies against S. stercoralis in
sera were investigated by a commercial ELISA kit (DRG
Strongyloides IgG, USA) according to the instructions of
manufacturers. In brief, serum samples were diluted 1:64
in dilution buffer and added antigen-coated wells. After
being incubated at room temperature for 10 min, the wells
were washed three times with the diluted wash buffer and
2 drops of enzyme conjugate were added to each well.

After incubation at room temperature for 5 min, the wells
were washed again and 2 drops of chromogen were added.
Following a 5 min of incubation, 2 drops of stop solution
were added and the reaction was stopped. The results were
read at 450 nm and 0.5 OD units and above were accepted
as positive results. Each serum sample was examined twice
at two different times.
All tests were performed in the Parasitology Section of
the Department of Medical Microbiology. The study
was approved by the Ethical Committee of Hacettepe
University.
3. Results
There was no difference between the two groups in terms
of age and sex. Epidemiologic and sociodemographic
features were similar.
Out of 100 patients, 24 were diagnosed with ankylosing
spondylitis and 14 with rheumatoid arthritis. All of these
rheumatology patients were receiving immunosuppressive
agents. Four of them were positive for S. stercoralis
antibodies. Two were diagnosed with ankylosing
spondylitis and treated with etanercept, methotrexate,
and prednisolone. Two patients had rheumatoid arthritis
and were taking infliximab and methotrexate. None of
these patients had symptoms, such as diarrhea, abdominal
pain, nausea, vomiting, cutaneous lesions, or respiratory
symptoms, that point to a parasitic infection. Eosinophil
levels were within normal range in all sera-positive patients.
There were 42 patients with malignancies in the study.
Twenty-four patients were receiving chemotherapy for
solid organ tumour and 18 for hematopoietic malignancies.
None of them were positive for S. stercoralis antibodies. In
two AIDS patients with diarrhea, S. stercoralis antibodies
were negative. Fourteen of the patients were receiving
immunosuppressive therapies for liver transplantation. S.
stercoralis antibodies were not detected in any of them. All
control patients were negative for S. stercoralis antibody
(Table).
Table. Clinical conditions and seropositivity of patients.
Clinical condition

Number

Ankylosing spondylitis

24

S. stercoralis antibody
positivity %
2

Rheumatoid arthritis

14

2

Solid organ tumour

24

0

Hematopoietic malignancies 18

0

Liver transplantation

14

0

Hypogammaglobulinemia

4

0

HIV-positive

2

0

Total

100

4%
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4. Conclusion
S. stercoralis infection can be severe and life-threatening
in patients with immunosuppression. Predisposing
risk factors for developing disseminated infection and
hyperinfection syndrome are immunosuppressive
therapies for immune-mediated disorders, infections with
the human immunodeficiency virus (HIV), hematopoietic
malignancies, and solid organ transplants (4). It is reported
that serological methods can be used as screening tests in
immunosuppressed patients and the sensitivity of ELISA
ranges from 80% to 100% (7,8).
In this preliminary study, our object was to evaluate
the S. stercoralis serology for the management of
probable chronic strongyloidiasis in patients with
immunosuppresion.
Taking high doses of corticosteroids or
antiinflammatory agents for rheumatoid diseases is a risk
factor for developing severe strongyloidiasis (9). Yanık
et al. reported S. stercoralis infection in a patient taking
corticosteroid and infliximab for several years because
of ankylosing spondylitis. The patient had no signs that
indicate S. stercoralis infection except high levels of IgE
and eosinophilia. Histological examination of endoscopic
duodenal biopsy revealed S. stercoralis larvae (10). There
are also hyperinfection syndromes with S. stercoralis in
rheumatology patients reported in the literature. Yılmaz
et al. presented a hyperinfection syndrome in a patient
with Behçet’s Disease on immunosuppressive treatment
(11). Altintop et al. and Das et al. reported hyperinfection
syndromes in patients with rheumatoid arthritis treated
with steroids and methotrexate (12,13). In our study, S.
stercoralis antibodies were found positive in rheumatology
patients who were receiving immunosuppressive drugs.
None of them had symptoms that point to a parasitic
infection. Eosinophil levels were also within the normal
range. In these patients, further investigations, such as
Baermann’s technique, stool culture, polymerase chain
reaction, or endoscopic duodenal biopsy, may be required
to detect possible S. stercoralis infection.
In oncology patients, diarrhea is one of the
complications of chemotherapy and may be disregarded
in terms of parasitic infection. There are reported cases of
strongyloidiasis in patients with malignancies receiving
immunosuppressive therapies (14). Zueter et al. studied
192 stool and serum samples collected from cancer
patients who were receiving chemotherapy. They found
that 1 (0.5%) sample was positive for S. stercoralis by
microscopy, 3 (1.6%) by real-time PCR, 8 (4.2%) by IgGELISA. In patients with malignancies, immunosuppressive
therapy can be the cause of fatal strongyloidiasis (15).
Although we found no seropositivity in oncology patients
in our study, it is important to follow up these individuals
in terms of developing parasitic infection.
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Strongyloidiasis is reported to be common in AIDS
patients in endemic areas. Jongwutiwes et al. reported
a case-control study for determining the prevalence and
risk factors of S. stercoralis infection. They found that
strongyloidiasis was seen more often in male patients
with eosinophilia and with HIV infection (9). Despite
the fact that prevalence rates of infection are higher in
the individuals with HIV, some researchers report that
hyperinfection syndrome is rarely seen in advanced HIV
disease because of increased Th2 response which may
protect against severe forms of strongyloidiasis (16-19). In
our study, there were two HIV-positive patients and they
both had diarrhea. S. stercoralis antibodies were found
negative in these individuals.
Several S. stercoralis infections in heart, kidney,
intestine, liver, and stem cell transplant patients have been
reported. In most of the cases, the infection was caused
by reactivation of latent infections; in a few cases, it was
acquired from the donors. Severe strongyloidiasis in
transplant patients reveals high mortality rates (20–24). We
did not detect S. stercoralis antibodies in patients receiving
immunosuppressive therapies for liver transplantation.
In Turkey, the prevalence of S. stercoralis infection is
reported between 0% and 4.4% based on stool examination
(25). Aksoy Gökmen et al. investigated the incidence of S.
stercoralis in individuals who live in rural areas and work
in the garden; one of 281 volunteers (0.3%) was positive
for S. stercoralis-IgG antibodies (26).
To our knowledge, this is the first study conducted
to detect the S. stercoralis seroprevalance of
immunosuppressed patients in Turkey. A total of 150 sera
sample were tested for the presence of IgG antibodies
against S. stercoralis. Four of 100 (4%) sera from
immunosuppressed patients were positive. In the control
group, all individuals were sera-negative. Limitations of
this study are low number of patients and inadequacy
of fecal tests due to poor compliance of patients to the
repeated stool examinations. Further investigation with
molecular techniques may be an alternative diagnostic
tool for the detection of S. stercoralis in these patients.
Although there were no signs of parasitic involvement
in our sera-positive patients, it might be beneficial to
follow up these patients in terms of developing S. stercoralis
infection. It is important to detect latent S. stercoralis
infections before administering chemotherapy or before
the onset of immunosuppression in patients at risk to
prevent severe complications.
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